FDA approved an expanded indication for Asceniv to include pediatric immune-compromised patients aged two years and older.
What this means
Asceniv is an antibody-based therapy used to boost the immune system in patients with weakened defenses. The FDA has now approved its use in children aged two and older who have compromised immune systems. This decision could provide younger patients with a new treatment option to help protect against infections and improve their quality of life.
